Efung Capital
倚锋资本
Efung Capital (倚锋资本) is a Chinese venture capital firm focused on the healthcare and biotech sector, with a particular concentration on pharmaceutical development and life sciences. The fund appears to operate primarily as a co-investor and follower in later-stage rounds rather than leading deals. In Gaorong's reporting, Efung has been noted as a participant in multiple financing rounds for Andao Pharmaceutical (安道药业), including a $50 million Series B in late 2021 and a follow-on in a 2024 Series C that raised over 400 million yuan . It also co-led a pre-A round for Westlake Omics (西湖欧米), a proteomics company, alongside Hillhouse's VC arm in early 2022 . Beyond these deal participations, elsewhere's corpus does not cover Efung's founding details, fund size, or full investment strategy.
AI-generated — may contain errors, please verify.
Coverage
Wanwu Capital Portfolio Company TanSheng WanWu Completes Series A Funding to Accelerate Direct Air Carbon Capture for Sustainable Aviation Fuel Production
"CO₂ is the oil of the new era."
Andon Therapeutics Raises Over 400 Million Yuan in Series C Funding to Accelerate Phase III Clinical Trials for Revolutionary Pan-Anemia Drug
Focused on R&D of novel drugs for kidney diseases, pan-anemia conditions, and cancer.
Securing Hundreds of Millions of Yuan in Pre-A Funding, How Westlake Omics Builds the AlphaFold of Proteomics | Gaorong "Future"
Deciphering the mathematical laws of the microscopic protein world to enable proteomics-based precision medicine.
Gaorong Monthly · December | Gaorong Ventures and Its Frontier Tech / Consumer / Healthcare / Enterprise Service Portfolio Companies Win Multiple Annual Awards
Its technological and innovative capabilities have won recognition.
Hangzhou Andao Pharma Closes $50 Million Series B to Advance Drug Development for Kidney Disease and Cancer
Addressing the enormous unmet clinical needs in nephrology and oncology.
